Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044287 | 0.82 | L3MBTL1 (0.46) | L3MBTL1NSD2ABL1PPARGRIN1 | |
| SCHEMBL30024442 | 0.82 | L3MBTL1 (0.46) | L3MBTL1NSD2ABL1PPARGRIN1 | |
| SCHEMBL6872834 | 0.81 | RHEB (0.48) | L3MBTL1NSD2ABL1PPARGRIN1 | |
| SCHEMBL20515877 | 0.79 | MEN1 (0.52) | PTGER1MEN1KMT2ASRD5A2 | |
| SCHEMBL29415608 | 0.78 | DRD4 (0.63) | L3MBTL1DRD2DRD4DRD3MAPT | |
| SCHEMBL746079 | 0.78 | DRD4 (0.63) | L3MBTL1DRD2DRD4DRD3MAPT | |
| SCHEMBL27483603 | 0.78 | BRD4 (0.50) | L3MBTL1NSD2ABL1PPARGRIN1 | |
| SCHEMBL3909627 | 0.78 | DRD2 (0.43) | KDM1AL3MBTL1NSD2ABL1PPARG | |
| SCHEMBL20905225 | 0.75 | TRPA1 (0.56) | L3MBTL1DRD2DRD4DRD3TRPA1 | |
| SCHEMBL6868530 | 0.75 | HPGD (0.55) | L3MBTL1PTGER1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635492-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4551212-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119698412-A | 5-HT2A receptor agonist, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2025-02-20 | — | — | US | disclosed |
| WO-2025021120-A1 | 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-117897376-A | Heterocyclic compounds and process for preparing same | 光明智慧生物科学公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4347561-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | Bright Minds Biosciences Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024035757-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2022246554-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2022-12-01 | — | — | WO | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | KDM1A 3195/4885L3MBTL1 2184/4885NSD2 2015/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | KDM1A 3195/4885L3MBTL1 2184/4885NSD2 2015/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | KDM1A 3195/4885L3MBTL1 2184/4885NSD2 2015/4885 |
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | OPRL1, OPRK1, CNR2 | KDM1A 4119/4885L3MBTL1 4682/4885NSD2 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.